We continuously invest in research into new medicines for serious diseases. In 2024, Amgen invested a total of €5,43 billion globally. Of this, €7,2 million was invested in R&D in 2024 in the Netherlands. These are expenses on non-clinical studies, clinical studies, prospective non-intervention studies, including related costs.

2024 R&D Transfer of value rapport Nederland (Update 26/05/2025)
2023 R&D Transfer of value rapport Nederland (Update 03/05/2024)
2022 R&D Transfer of value rapport Nederland (Update 03/06/2023)
2021 R&D Transfer of value rapport Nederland (Update 03/06/2022)
2020 R&D Transfer of value rapport Nederland (Update 27/05/2021)
EFPIA Disclosure Code Methodological Note (English)
Amgen EFPIA Disclosure Code Self-Certification Scheme

1Converted from US$ by XE currency converter, accessed 16 June 2023